APLS Apellis Pharmaceuticals, Inc.

Nasdaq apellis.com


$ 24.00 $ 0.00 (0 %)    

Friday, 17-Oct-2025 07:29:24 EDT
QQQ $ 599.15 $ 0.00 (0 %)
DIA $ 460.14 $ 0.00 (0 %)
SPY $ 661.01 $ 0.00 (0 %)
TLT $ 91.09 $ 0.00 (0 %)
GLD $ 396.42 $ 0.00 (0 %)
$ 24.15
$ 25.22
$ 24.00 x 3
$ 25.20 x 80
-- - --
$ 16.10 - $ 35.72
1,544,291
na
3.05B
$ 0.85
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-31-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 02-28-2025 01-01-1970 10-K
4 11-05-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 02-27-2024 12-31-2023 10-K
8 11-01-2023 09-30-2023 10-Q
9 07-31-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-21-2023 12-31-2022 10-K
12 11-07-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-04-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-08-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 04-28-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 11-02-2020 09-30-2020 10-Q
21 07-30-2020 06-30-2020 10-Q
22 04-29-2020 03-31-2020 10-Q
23 02-27-2020 12-31-2019 10-K
24 11-05-2019 09-30-2019 10-Q
25 07-31-2019 06-30-2019 10-Q
26 05-07-2019 03-31-2019 10-Q
27 02-26-2019 12-31-2018 10-K
28 11-13-2018 09-30-2018 10-Q
29 07-31-2018 06-30-2018 10-Q
30 04-30-2018 03-31-2018 10-Q
31 03-19-2018 12-31-2017 10-K
32 12-20-2017 09-30-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wells-fargo-upgrades-apellis-pharmaceuticals-to-overweight-raises-price-target-to-32

Wells Fargo analyst Derek Archila upgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Equal-Weight to Overweight and raises ...

 12-analysts-assess-apellis-pharmaceuticals-what-you-need-to-know

During the last three months, 12 analysts shared their evaluations of Apellis Pharmaceuticals (NASDAQ: APLS), revealing diverse...

 goldman-sachs-downgrades-apellis-pharmaceuticals-to-sell-lowers-price-target-to-18

Goldman Sachs analyst Salveen Richter downgrades Apellis Pharmaceuticals (NASDAQ: APLS) from Neutral to Sell and lowers the ...

 concentrix-posts-downbeat-earnings-joins-legacy-education-kingsoft-cloud-and-other-big-stocks-moving-lower-in-fridays-pre-market-session

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Friday.

 why-top-kingwin-shares-are-trading-higher-by-87-here-are-20-stocks-moving-premarket

Shares of Top KingWin Ltd (NASDAQ: WAI) rose sharply in pre-market trading after the company announced it entered into a sales ...

 jp-morgan-maintains-overweight-on-apellis-pharmaceuticals-raises-price-target-to-37

JP Morgan analyst Anupam Rama maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Overweight and raises the price target ...

 citigroup-maintains-buy-on-apellis-pharmaceuticals-raises-price-target-to-52

Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and raises the price target f...

 rbc-capital-maintains-sector-perform-on-apellis-pharmaceuticals-raises-price-target-to-19

RBC Capital analyst Lisa Walter maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Sector Perform and raises the price t...

 cantor-fitzgerald-maintains-overweight-on-apellis-pharmaceuticals-raises-price-target-to-40

Cantor Fitzgerald analyst Steve Seedhouse maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Overweight and raises the p...

 raymond-james-maintains-outperform-on-apellis-pharmaceuticals-lowers-price-target-to-50

Raymond James analyst Ryan Deschner maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and lowers the price t...

 apellis-pharmaceuticals-q2-eps-033-beats-048-estimate-sales-178494m-miss-187790m-estimate

Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate ...

 citigroup-maintains-buy-on-apellis-pharmaceuticals-raises-price-target-to-46

Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and raises the price target f...

 fda-approval-for-empaveli-marks-key-milestone-in-apellis-rare-disease-portfolio

FDA approves Apellis' Empaveli for rare kidney diseases, with trial data showing strong efficacy in reducing proteinuria an...

 reported-earlier-apellis-wins-fda-approval-for-empaveli-to-treat-rare-kidney-diseases-c3g-and-ic-mpgn-with-68-proteinuria-reduction

Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and sub...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION